TrialStudy of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Trial details
- Registry ID
- NCT05177770
- Phase
- Phase 2
CHRS
Coherus Oncology, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerNCT05177770 | CHRS | Phase 2 | Terminated | 2023-04-05Actual |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861 | CHRS | Phase 2 | Completed | 2025-06-30Actual |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985 | CHRS | Phase 2 | Active not recruiting | 2027-09Estimated |
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT05359861
- Phase
- Phase 2
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT06679985
- Phase
- Phase 2
Latest recorded trial changes
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985 · Coherus Oncology, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
NCT05359861 · Coherus Oncology, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
134 participants (planned)
+ After
30 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Aug 2025
+ After
30 Jun 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Completed